Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2011 (2011), Article ID 486305, 6 pages
http://dx.doi.org/10.1155/2011/486305
Review Article

Role of Mindin in Diabetic Nephropathy

Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan

Received 25 July 2011; Accepted 26 September 2011

Academic Editor: Yoshio Shimizu

Copyright © 2011 Maki Murakoshi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Ismail, B. Becker, P. Strzelczyk, and E. Ritz, “Renal disease and hypertension in non-insulin-dependent diabetes mellitus,” Kidney International, vol. 55, no. 1, pp. 1–28, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. S. Krolewski, J. H. Warram, L. I. Rand, and C. R. Kahn, “Epidemiologic approach to the etiology of type I diabetes mellitus and its complications,” New England Journal of Medicine, vol. 317, no. 22, pp. 1390–1398, 1987. View at Google Scholar · View at Scopus
  3. J. C. Pickup, “Inflammation and activated innate immunity in the pathogenesis of type 2 diabletes,” Diabetes Care, vol. 27, no. 3, pp. 813–823, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Crook, “Type 2 diabetes mellitus: a disease of the innate immune system? An update,” Diabetic Medicine, vol. 21, no. 3, pp. 203–207, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Festa, R. D'Agostino, R. P. Tracy, and S. M. Haffner, “Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study,” Diabetes, vol. 51, no. 4, pp. 1131–1137, 2002. View at Google Scholar · View at Scopus
  6. A. Rivero, C. Mora, M. Muros, J. García, H. Herrera, and J. F. Navarro-González, “Pathogenic perspectives for the role of inflammation in diabetic nephropathy,” Clinical Science, vol. 116, no. 6, pp. 479–492, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. C. Pickup and M. A. Crook, “Is type II diabetes mellitus a disease of the innate immune system?” Diabetologia, vol. 41, no. 10, pp. 1241–1248, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. F. Navarro and C. Mora, “Role of inflammation in diabetic complications,” Nephrology Dialysis Transplantation, vol. 20, no. 12, pp. 2601–2604, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. Mora and J. F. Navarro, “Inflammation and diabetic nephropathy,” Current Diabetes Reports, vol. 6, no. 6, pp. 463–468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. W. J. Jeffcoate, F. Game, and P. R. Cavanagh, “The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes,” Lancet, vol. 366, no. 9502, pp. 2058–2061, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. N. Demircan, B. G. Safran, M. Soylu, A. A. Ozcan, and S. Sizmaz, “Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy,” Eye, vol. 20, no. 12, pp. 1366–1369, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. G. Hasegawa, K. Nakano, M. Sawada et al., “Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy,” Kidney International, vol. 40, no. 6, pp. 1007–1012, 1991. View at Google Scholar · View at Scopus
  13. J. F. Navarro, C. Mora, M. Maca, and J. García, “Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus,” American Journal of Kidney Diseases, vol. 42, no. 1, pp. 53–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. F. Navarro, C. Mora, A. Rivero et al., “Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration,” American Journal of Kidney Diseases, vol. 33, no. 3, pp. 458–463, 1999. View at Google Scholar · View at Scopus
  15. J. A. Royall, R. L. Berkow, J. S. Beckman, M. K. Cunningham, S. Matalon, and B. A. Freeman, “Tumor necrosis factor and interleukin 1 α increase vascular endothelial permeability,” American Journal of Physiology, vol. 257, pp. L399–L410, 1989. View at Google Scholar
  16. C. Melcion, L. Lachman, and P. D. Killen, “Mesangial cells, effect of monocyte products on proliferation and matrix synthesis,” Transplantation Proceedings, vol. 14, no. 3, pp. 559–564, 1982. View at Google Scholar · View at Scopus
  17. T. Lenz, T. Haak, J. Malek, H. J. Gröne, H. Geiger, and J. Gossmann, “Vascular endothelial growth factor in diabetic nephropathy,” Kidney and Blood Pressure Research, vol. 26, no. 5-6, pp. 338–343, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. H. S. Lim, G. Y. Lip, and A. D. Blann, “Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis,” Atherosclerosis, vol. 180, no. 1, pp. 113–118, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. N. Banba, T. Nakamura, M. Matsumura, H. Kuroda, Y. Hattori, and K. Kasai, “Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy,” Kidney International, vol. 58, no. 2, pp. 684–690, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. G. H. Tesch, “MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy,” American Journal of Physiology—Renal Physiology, vol. 294, no. 4, pp. F697–F701, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. S. Chen, B. Jim, and F. N. Ziyadeh, “Diabetic nephropathy and transforming growth factor-β: transforming our view of glomerulosclerosis and fibrosis build-up,” Seminars in Nephrology, vol. 23, no. 6, pp. 532–543, 2003. View at Google Scholar · View at Scopus
  22. J. F. Navarro, F. J. Milena, C. Mora et al., “Tumor necrosis factor-α gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition,” Kidney International, vol. 68, no. 99, pp. S-98–S-102, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. E. T. Mccarthy, R. Sharma, M. Sharma et al., “TNF-α increases albumin permeability of isolated rat glomeruli through the generation of superoxide,” Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 433–438, 1998. View at Google Scholar · View at Scopus
  24. K. Kalantarinia, A. S. Awad, and H. M. Siragy, “Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats,” Kidney International, vol. 64, no. 4, pp. 1208–1213, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. Murakoshi, M. Tanimoto, T. Gohda et al., “Mindin: a novel marker for podocyte injury in diabetic nephropathy,” Nephrology Dialysis Transplantation, vol. 26, no. 7, pp. 2153–2160, 2011. View at Publisher · View at Google Scholar · View at PubMed
  26. Y. W. He, H. Li, J. Zhang et al., “The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens,” Nature Immunology, vol. 5, no. 1, pp. 88–97, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. W. Jia, H. Li, and Y. W. He, “The extracellular matrix protein mindin serves as an integrin ligand and is critical for inflammatory cell recruitment,” Blood, vol. 106, no. 12, pp. 3854–3859, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. H. Li, T. Oliver, W. Jia, and Y. W. He, “Efficient dendritic cell priming of T lymphocytes depends on the extracellular matrix protein mindin,” EMBO Journal, vol. 25, no. 17, pp. 4097–4107, 2006. View at Publisher · View at Google Scholar · View at PubMed
  29. W. Jia, H. Li, and Y. W. He, “Pattern recognition molecule mindin promotes intranasal clearance of influenza viruses,” Journal of Immunology, vol. 180, no. 9, pp. 6255–6261, 2008. View at Google Scholar
  30. Z. Li, S. Garantziotis, W. Jia et al., “The extracellular matrix protein mindin regulates trafficking of murine eosinophils into the airspace,” Journal of Leukocyte Biology, vol. 85, no. 1, pp. 124–131, 2009. View at Publisher · View at Google Scholar · View at PubMed
  31. B. Guleng, Y. M. Lian, and J. L. Ren, “Mindin is upregulated during colitis and may activate NF-κB in a TLR-9 mediated manner,” World Journal of Gastroenterology, vol. 16, no. 9, pp. 1070–1075, 2010. View at Publisher · View at Google Scholar
  32. A. Klar, M. Baldassare, and T. M. Jessell, “F-spondin: a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension,” Cell, vol. 69, no. 1, pp. 95–110, 1992. View at Publisher · View at Google Scholar
  33. S. Higashijima, A. Nose, G. Eguchi, Y. Hotta, and H. Okamoto, “Mindin/F-spondin family: novel ECM proteins expressed in the zebrafish embryonic axis,” Developmental Biology, vol. 192, no. 2, pp. 211–227, 1997. View at Publisher · View at Google Scholar
  34. T. Umemiya, M. Takeichi, and A. Nose, “M-spondin, a novel ECM protein highly homologous to vertebrate F- spondin, is localized at the muscle attachment sites in the Drosophila embryo,” Developmental Biology, vol. 186, no. 2, pp. 165–176, 1997. View at Publisher · View at Google Scholar · View at PubMed
  35. Y. Feinstein, V. Borrell, C. Garcia et al., “F-spondin and mindin: two structurally and functionally related genes expressed in the hippocampus that promote outgrowth of embryonic hippocampal neurons,” Development, vol. 126, no. 16, pp. 3637–3648, 1999. View at Google Scholar
  36. R. Manda, T. Kohno, Y. Matsuno, S. Takenoshita, H. Kuwano, and J. Yokota, “Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display,” Genomics, vol. 61, no. 1, pp. 5–14, 1999. View at Publisher · View at Google Scholar · View at PubMed
  37. S. Zisman, K. Marom, O. Avraham et al., “Proteolysis and membrane capture of F-spondin generates combinatorial guidance cues from a single molecule,” Journal of Cell Biology, vol. 178, no. 7, pp. 1237–1249, 2007. View at Publisher · View at Google Scholar · View at PubMed
  38. J. C. Adams and R. P. Tucker, “The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development,” Developmental Dynamics, vol. 218, no. 2, pp. 280–299, 2000. View at Publisher · View at Google Scholar
  39. Y. Li, C. Cao, W. Jia et al., “Structure of the F-spondin domain of mindin, an integrin ligand and pattern recognition molecule,” EMBO Journal, vol. 28, no. 3, pp. 286–297, 2009. View at Publisher · View at Google Scholar · View at PubMed
  40. C. McDonald and G. Nuñez, “Mindin the fort,” Nature Immunology, vol. 5, no. 1, pp. 16–18, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. S. Decramer, A. G. de Peredo, B. Breuil et al., “Urine in clinical proteomics,” Molecular and Cellular Proteomics, vol. 7, no. 10, pp. 1850–1862, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. M. Okazaki, Y. Saito, Y. Udaka et al., “Diabetic nephropathy in KK and KK-Ay mice,” Experimental Animals, vol. 51, no. 2, pp. 191–196, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Asanuma and P. Mundel, “The role of podocytes in glomerular pathobiology,” Clinical and Experimental Nephrology, vol. 7, no. 4, pp. 255–259, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. S. Adler, “Characterization of glomerular epithelial cell matrix receptors,” American Journal of Pathology, vol. 141, no. 3, pp. 571–578, 1992. View at Google Scholar · View at Scopus
  45. C. J. Raats, J. van den Born, M. A. Bakker et al., “Expression of agrin, dystroglycan, and utrophin in normal renal tissue and in experimental glomerulopathies,” American Journal of Pathology, vol. 156, no. 5, pp. 1749–1765, 2000. View at Google Scholar · View at Scopus
  46. H. M. Regele, E. Fillipovic, B. Langer et al., “Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis,” Journal of the American Society of Nephrology, vol. 11, no. 3, pp. 403–412, 2000. View at Google Scholar · View at Scopus